Sign in

You're signed outSign in or to get full access.

TI

Talkspace, Inc. (TALK)·Q3 2024 Earnings Summary

Executive Summary

  • Q3 2024 revenue rose 22.6% year over year to $47.4M, driven by Payor +45% and DTE +17%; gross margin was 45.6% and adjusted EBITDA reached $2.4M, marking the third consecutive quarter of adjusted EBITDA profitability .
  • GAAP net income was $1.9M vs $(4.4)M in Q3 2023; diluted EPS $0.01 vs $(0.03) last year; cash ended at $118.994M (CFO noted ~$119M, up sequentially) .
  • Guidance reaffirmed: FY2024 revenue $185–$195M and adjusted EBITDA $4–$8M; management signaled expectation to land at the high end of EBITDA range given OpEx initiatives .
  • Key catalysts: expanding covered lives (158.1M now; Medicare CMS approvals ~40 states, live in 30), TRICARE East launch (6M lives), and Amazon Health Services partnership to drive high-intent referrals; new teen community product and broader DTE pipeline support momentum into 2025 .

What Went Well and What Went Wrong

What Went Well

  • Strong Payor growth: Payor revenue +44.9% YoY to $32.0M; sessions +38% YoY to ~316k; unique active Payor members +24% YoY; sequential sessions +6% .
  • Profitability and operating discipline: Adjusted EBITDA $2.4M (vs $(2.8)M LY) and normalized OpEx down ~11% YoY; management highlighted ~100% sequential adjusted EBITDA increase and OpEx optimization benefits .
  • Strategic partnerships expanding funnel: Amazon Health Services (first behavioral partner) to increase discoverability; Medicare Advantage expansion; TRICARE East (6M lives); teens product and DTE wins (e.g., PTPA) .

What Went Wrong

  • Gross margin compression to 45.6% from 48.8% LY due to revenue mix shifting toward Payor; gross profit growth (+14.7% YoY) lagged revenue growth .
  • Consumer revenue decline: down 29.8% YoY to $6.0M and 8% sequentially, reflecting in-network marketing focus and mix optimization; management expects consumer to be smaller, with persistent but moderated declines .
  • DTE sequential dip (−2%) from contract expirations despite +17% YoY; longer enterprise sales cycles (esp. teen vertical) continue, though pipeline remains strong .

Financial Results

MetricQ3 2023Q1 2024Q2 2024Q3 2024
Revenue ($USD Millions)$38.646 $45.416 $46.058 $47.399
Gross Profit ($USD Millions)$18.849 $21.731 $20.951 $21.621
Gross Margin %48.8% 47.8% 45.5% 45.6%
Net Income (Loss) ($USD Millions)$(4.414) $(1.466) $(0.474) $1.874
Diluted EPS ($USD)$(0.03) $(0.01) $(0.00) $0.01
Adjusted EBITDA ($USD Millions)$(2.800) $0.774 $1.179 $2.350
Adjusted EBITDA Margin %5.0%

Segment revenue breakdown:

Segment Revenue ($USD Millions)Q3 2023Q1 2024Q2 2024Q3 2024
Payor$22.112 $28.508 $29.945 $32.039
Direct-to-Enterprise (DTE)$8.002 $9.913 $9.628 $9.370
Consumer$8.532 $6.995 $6.485 $5.990
Total$38.646 $45.416 $46.058 $47.399

Selected KPIs:

KPIQ3 2023Q1 2024Q2 2024Q3 2024
Eligible lives at period end (Millions)113.0 131.4 145.3 158.1
Completed Payor sessions (Thousands)228.6 284.2 298.6 316.4
Consumer active members at period end (Millions)13.3 11.1 10.7 8.6
Cash & Equivalents ($USD Millions)$125.332 $120.278 $114.913 $118.994

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Revenue ($USD Millions)FY 2024$185–$195 $185–$195 Maintained
Adjusted EBITDA ($USD Millions)FY 2024$4–$8 $4–$8 Maintained

Management commentary: expect FY2024 EBITDA to finish at the high end of range given OpEx actions (not formal guidance change) .

Earnings Call Themes & Trends

TopicPrevious Mentions (Q1 & Q2 2024)Current Period (Q3 2024)Trend
AI/technology initiativesLaunched AI-backed provider documentation; provider network expansion ; AI Smart Notes and secure captions; most productive therapist billable hours AI Smart Notes drove ~3% provider efficiency; focus on scaling features to reduce admin burden Accelerating adoption; measurable productivity gains
Payor growth & captureCovered lives 131.4M → 145.3M; focus on capture/retention and co-pay transparency Covered lives 158.1M; Payor sessions +38% YoY; capture rate improvements continue Sustained growth; improving utilization
Medicare & MilitaryMedicare available in 12 states; targeting 50 by year-end; TRICARE East launch announced CMS approvals ~40 states, live in 30; TRICARE East live covering ~6M; goal ~200M covered lives in 2025 Ramping presence; 2025 top-line driver
Strategic partnerships/referralsWomen’s Health coalition; brand awareness up despite lower ad spend Amazon Health Services (first behavioral partner); Wisdo Health (loneliness for seniors); DTE PTPA Broadening referral channels; capital-light awareness
Teens product/performanceNYC Teenspace: 13k users; 180 high-risk interventions; new wins across schools Launch of Teenspace Community; 7 new school districts; continued strong pipeline Expanding teen ecosystem
Value-based careNot highlightedEarly-stage value-based contracts signed; metrics include time-to-eval, access, follow-up within 30 days Emerging; aligned with capabilities

Management Commentary

  • “For the third quarter, revenue increased 23% year-over-year to $47.4 million, and we delivered our third consecutive profitable quarter with adjusted EBITDA coming in at $2.4 million… Payor grew 45% year-over-year… total covered lives to nearly 160 million people, an increase of 40% year-over-year” .
  • “As of this month, we are now CMS approved in approximately 40 states and live in 30… We launched TRICARE East in August, covering 6 million active duty and retired military lives… we expect to be in network nationally… in early 2025” .
  • “This new feature [AI Smart Notes] drove a 3% increase in efficiency where providers were able to conduct more sessions during the same working hours” .
  • “We reaffirmed our 2024 financial guidance… $185 million to $195 million in revenue and adjusted EBITDA between $4 million and $8 million for the full year” .
  • “Being the only behavioral health partner on the [Amazon] health conditions platform is a very important deal… driving high-intent potential users of Talkspace to us in a manner that's in network” .

Q&A Highlights

  • Amazon partnership: announced Sept 27; de minimis Q3 impact; expected to drive high-intent, in-network traffic; validation of therapist network moat; pursuing similar channels (e.g., ZocDoc) .
  • FY2024 outlook: revenue tracking a little below midpoint; EBITDA expected at high end of range given OpEx actions; Medicare/Military initiatives to be 2025 top-line drivers .
  • Consumer dynamics: shift to in-network benefits reduces B2C mix; persistent consumer segment remains (high deductibles, privacy); declines moderating vs 2023–2024 step-downs .
  • CAC/marketing: dynamic, data-driven spend; election-year inflation avoided; CAC varies by segment (Medicare vs Military vs Teens); brand awareness up with lower ad spend .
  • Value-based contracting: early-stage deals signed; operational metrics (time to eval, access windows, follow-up) fit current capabilities .

Estimates Context

  • S&P Global consensus estimates for Q3 2024 were unavailable at the time of request due to API limits; comparisons vs Street were not provided. We will update beat/miss analysis once S&P Global data access is restored.

Key Takeaways for Investors

  • Payor-led growth continues with improving utilization; mix shift compresses gross margin but expands adjusted EBITDA and operating leverage .
  • Guidance intact; management expects FY2024 EBITDA at high end, driven by OpEx optimization; sequential EBITDA momentum likely into Q4 .
  • 2025 setup: Medicare (CMS approvals/live states, Medicare Advantage) and TRICARE national rollout are positioned to reaccelerate top line as go-to-market scales .
  • Capital-light referral channels (Amazon Health Services, Wisdo) should improve capture rates and reduce CAC; brand awareness rising with lower paid media .
  • Teens vertical is a distinct growth pillar with new product (Teenspace Community) and expanding district wins; supports DTE resilience despite contract churn .
  • Early value-based contracts align with Talkspace’s access/quality infrastructure; should strengthen payor relationships and potential economics over time .
  • Near-term trading: watch Q4 adjusted EBITDA delivery and any Medicare Advantage announcements; medium term thesis hinges on execution of Medicare/Military activation and sustained Payor capture rate improvements .